

# Georg Aue

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8376971/publications.pdf>

Version: 2024-02-01

21  
papers

673  
citations

1162889

8  
h-index

752573

20  
g-index

21  
all docs

21  
docs citations

21  
times ranked

1213  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2021, 193, 951-960.	1.2	8
2	A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients. <i>British Journal of Haematology</i> , 2020, 189, 551-558.	1.2	17
3	Ex Vivo Nicotinamide-Expanded (NAM-Expanded) Unrelated Cord Bloodtransplantation (UCB) for Refractory Severe Aplastic Anemia Results in Rapid Engraftment and Expedites Immune Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S210-S211.	2.0	3
4	Acute Epiglottitis in the Immunocompromised Host: Case Report and Review of the Literature. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy038.	0.4	7
5	Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , 2018, 201, 1967-1974.	0.4	22
6	Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. <i>Leukemia</i> , 2017, 31, 1340-1347.	3.3	103
7	Allogeneic transplantation using $CD34^{+}$ selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia. <i>British Journal of Haematology</i> , 2017, 176, 950-960.	1.2	7
8	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2015, 16, 169-176.	5.1	344
9	Harnessing the Fc $\gamma$ Receptor for Potent and Selective Cytotoxic Therapy of Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2014, 74, 7510-7520.	0.4	13
10	In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity. <i>Blood</i> , 2013, 122, 4182-4182.	0.6	5
11	Ibrutinib (PCI 32765) Rapidly Improves Platelet Counts in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) Patients and Has Minimal Effects On Platelet Aggregation. <i>Blood</i> , 2012, 120, 1789-1789.	0.6	10
12	In Vivo Effects of Ibrutinib On BCR Signaling, Tumor Cell Activation and Proliferation in Blood and Tissue-Resident Cells of Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2012, 120, 185-185.	0.6	2
13	Inflammation, TNF $\alpha$ and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2011, 86, 835-840.	2.0	34
14	The Bruton Tyrosine Kinase Inhibitor, PCI-32765, Inhibits Activation and Proliferation of Human Chronic Lymphocytic Leukemia Cells in the NSG Xenograph Mouse Model of the Tissue Microenvironment. <i>Blood</i> , 2011, 118, 596-596.	0.6	2
15	Correlates of Lenalidomide Induced Immune Stimulation and Response in CLL: Analysis in Patients on Treatment. <i>Blood</i> , 2011, 118, 979-979.	0.6	2
16	Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. <i>Haematologica</i> , 2009, 94, 1266-1273.	1.7	85
17	A Phase II Trial of Pulse Dosing Lenalidomide: 3 Weeks On 3 Weeks off in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.. <i>Blood</i> , 2009, 114, 3427-3427.	0.6	2
18	Increased Incidence of Thrombosis with Lenalidomide in Chronic Lymphocytic Leukemia: Effect of Lenalidomide On Inflammation, Endothelial Cell Damage and Coagulation.. <i>Blood</i> , 2009, 114, 455-455.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Sox4 Downregulates Pu.1 Gene Expression by Binding to An Upper Regulatory Element of Pu.1, a Mechanism Contributing to Leukemogenesis.. Blood, 2009, 114, 3979-3979.	0.6	0
20	Lenalidomide Induced Cytokine Release Syndrome in Chronic Lymphocytic Leukemia (CLL): Clinical and Laboratory Correlates of Immune Activation.. Blood, 2008, 112, 2099-2099.	0.6	2
21	Streptococcus pneumoniae sepsis in concurrently diagnosed multiple myeloma. American Journal of Hematology, 2007, 82, 858-858.	2.0	4